Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression
Launched by H. LUNDBECK A/S · Jun 23, 2020
Trial Information
Current as of June 06, 2025
Completed
Keywords
ClinConnect Summary
The study will consist of a screening period of up to 14 days before the Baseline Visit, followed by an 8-week Treatment Period with vortioxetine or desvenlafaxine. A Safety Follow-up Visit will be performed approximately 4 weeks after the Primary Outcome/Withdrawal Visit.
At Baseline, patients will be equally randomised (1:1) to 1 of the 2 treatment groups for an 8-week, double-blind Treatment Period.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The patient has a primary diagnosis of single or recurrent MDD, diagnosed according to DSM-5®. The current MDE must be confirmed using the Mini International Neuropsychiatric Interview (MINI).
- • The patient has a MADRS total score ≥24 at screening and baseline.
- • The patient has had the current MDE for ≥3 months and \< 12 months.
- • The patient has been treated with an SSRI as monotherapy (citalopram, escitalopram, paroxetine, sertraline) for at least 6 weeks at licensed dose for the current MDE with a partial response and is a candidate for a switch in the investigator's opinion.
- • The patient wants to switch antidepressant treatment.
- Exclusion Criteria:
- • The patient has any other disorder for which the treatment takes priority over treatment of MDD or is likely to interfere with study treatment or impair treatment compliance.
- • Other in- and exclusion criteria may apply
About H. Lundbeck A/S
H. Lundbeck A/S is a global pharmaceutical company dedicated to improving the quality of life for patients with brain disorders. Founded in 1915 and headquartered in Denmark, Lundbeck specializes in research, development, manufacturing, and marketing of innovative treatments for conditions such as depression, schizophrenia, and Alzheimer's disease. With a strong commitment to neuroscience, Lundbeck invests significantly in clinical trials to advance the understanding and treatment of psychiatric and neurological disorders, aiming to deliver effective solutions that address unmet medical needs worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saratov, , Russian Federation
Barcelona, , Spain
Rostov On Don, , Russian Federation
Moscow, , Russian Federation
Alcorcon, Madrid, Spain
Rimavska Sobota, , Slovakia
Zlate Moravce, , Slovakia
Bratislava, , Slovakia
Plzen, , Czechia
Varna, , Bulgaria
Tallinn, , Estonia
Monterrey, Nuevo Leon, Mexico
Arkhangelsk, , Russian Federation
Engels, , Russian Federation
Yaroslavl, , Russian Federation
Odessa, , Ukraine
Sigulda, , Latvia
Nizhny Novgorod, , Russian Federation
Praha 8, , Czechia
Lund, , Sweden
Banfield, Buenos Aires, Argentina
Ciudad Autonoma De Buenos Aires, Buenos Aires, Argentina
Ciudad Autonoma De Buenos Aires, Buenos Aires, Argentina
Ciudad Autonoma De Buenos Aires, Buenos Aires, Argentina
La Plata, Buenos Aires, Argentina
La Plata, Buenos Aires, Argentina
Cordoba, Providencia De Cordo, Argentina
Rosario, Santa Fe, Argentina
Ciudad Autonoma De Buenos Aires, , Argentina
Cordoba, , Argentina
Cordoba, , Argentina
Cordoba, , Argentina
Mendoza, , Argentina
Mendoza, , Argentina
Brugge, , Belgium
Duffel, , Belgium
Yvoir, , Belgium
Kazanlak, , Bulgaria
Plovdiv, , Bulgaria
Rousse, , Bulgaria
Samokov, , Bulgaria
Sofia, , Bulgaria
Prague, Prague 10, Czechia
Brno, , Czechia
Havirov, , Czechia
Hostivice, , Czechia
Hradec Kralove, , Czechia
Klecany, , Czechia
Kutna Hora, , Czechia
Liepaja, Liepajas Rajons, Latvia
Riga, , Latvia
Merida, Yucatan, Mexico
Ciudad De Mexico, , Mexico
Stavropol Region, Kochubeev District, Russian Federation
Roshchino, Leningrad Region, Russian Federation
Moscow, , Russian Federation
Rostov On Don, , Russian Federation
Saint Petersburg, , Russian Federation
Saint Petersburg, , Russian Federation
Smolensk, , Russian Federation
St. Petersburg, , Russian Federation
Kosice, , Slovakia
Vranov Nad Topou, , Slovakia
Zlate Moravce, , Slovakia
Oviedo, Asturias, Spain
Palma De Mallorca, , Spain
Malmo, Skane, Sweden
Halmstad, , Sweden
Skövde, , Sweden
Stockholm, , Sweden
Smila, Cherkasy, Ukraine
Kharkiv, Kharkivska, Ukraine
Kominternivskyy, Odesa, Ukraine
Glevakha, , Ukraine
Ivano Frankivsk, , Ukraine
Kharkiv, , Ukraine
Kharkiv, , Ukraine
Lviv, , Ukraine
Poltava, , Ukraine
Vinnitsa, , Ukraine
Patients applied
Trial Officials
Email contact via H. Lundbeck A/S
Study Director
LundbeckClinicalTrials@Lundbeck.com
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials